Randomized Phase II Trial of Panitumumab, Erlotinib and Gemcitabine vs. Erlotinib and Gemcitabine in Patients With Untreated, Metastatic Pancreatic Adenocarcinoma.
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Panitumumab (Primary) ; Erlotinib; Gemcitabine
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 07 Jun 2011 Results presented at the 47th Annual Meeting of the American Society of Clinical Oncology.
- 10 May 2011 Actual end date (Nov 2010) added as reported by ClinicalTrials.gov.
- 10 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.